01 8Orkambi
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2019 Revenue in Millions : 1,176
2018 Revenue in Millions : 1,262
Growth (%) : -7
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 908
2019 Revenue in Millions : 1,176
Growth (%) : -23
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 772
2020 Revenue in Millions : 908
Growth (%) : -18
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2022 Revenue in Millions : 511
2021 Revenue in Millions : 772
Growth (%) : -34
Main Therapeutic Indication : Genetic Diseases
Currency : USD
2023 Revenue in Millions : 326
2022 Revenue in Millions : 511
Growth (%) : -57
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2016 Revenue in Millions : 980
2015 Revenue in Millions : 351
Growth (%) : 179
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2017 Revenue in Millions : 1,321
2016 Revenue in Millions : 980
Growth (%) : 35
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2018 Revenue in Millions : 1,262
2017 Revenue in Millions : 1,321
Growth (%) : -4%
LOOKING FOR A SUPPLIER?